 |
凯发k8国际首页登录
凯发k8国际首页登录创立于2011年，专注于重大疾病诊疗新产品新技术的转化研究和研发，聚焦纳米医药技术，包括纳米载药技术、通用纳米晶技术、膜囊泡载药技术、肿瘤个体化纳米疫苗技术等，为肿瘤、心血管和炎症等疾病方向的研究组织和机构提供临床转化和研发支持。平台齐备纳米药物设计、合成、表征，药理药效、体内外生物学评价和机制研究等实验室，可快速产出重大疾病诊疗创新医药技术成果；拥有生产和销售数万种转化医学研究实验相关试剂耗材的资质，和顶级研究型三甲医院1100多个专家组深度合作，可保障转化和研发项目的高效实施。
凯发k8国际首页登录通过AAA级信用企业认证、ISO9001质量管理体系认证和ISO27001信息安全管理体系认证，项目实施管理采用高效智能科研ERP系统，符合GLP、GMP和GCP标准，并严格遵循医学研究规范和伦理。
近十年的积累与发展，凯发k8国际首页登录作为研究转化平台，为研究者、医健企业提供研究转化所需的技术支持，拥有多条新药研发管线，并设有“普略医学研究院”。凯发k8国际首页登录一直以“一个研究院+一个转化平台+多个研发管线”的模式高效运转，为医疗健康领域的进步贡献力量，秉承“引领医学科研，提升人类健康”、“攻克重大疾病”的愿景和使命，为社会创造转化医学价值。
|
|
ntroduction to 100Biotech technologies (HangZhou) Co., Ltd.
100Biotech was founded in 2011, which concentrates on translational research of new products and technologies for major disease’s diagnosis and treatments. It focuses on nanomedicine technology, exosomes, and novel RNA to provide translational medicine research for the research organizations and institutions in the field of tumors, cardiovascular, inflammation and so on. It is fully equipped with laboratories for design, synthesis, and characterization of nanodrugs, isolation, identification and detection of exosomes, screening, characterization, and generation mechanism analysis of novel RNA, in vitro and in vivo biological evaluation and mechanism research, which can produce innovative results quickly. It has qualification of producing and selling tens of thousands of medical reagents and consumables to efficiently guarantee the implementation of research and development. |
 |
|
100Biotech is a AAA credit enterprise, which has passed ISO9001 quality management system certification and ISO27001 information security management system certification. 100Biotech conforms to GLP, GMP and GCP standards, and follows the medical research norms and ethics strictly, while the project management adopts the efficient and intelligent ERP system.
Undergoing ten years accumulating and development, 100Biotech as a research and transformation platform, provides researchers and medical enterprises with the technical supports for translational research, which has multiple new drug research and development pipelines, and set up "100Biotech Medicine Research Institute". 100Biotech runs efficiently with the model of "one research institute + one transformation platform + multiple research and development pipelines", contributes to the advances of healthcare. 100Biotech will take the vision of “Leading Medical Research, Improving Human Health” and the mission of “Conquer Major Diseases”， to create translational medical value for the society. |
|
